Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, procarbazine, doxorubicin, bleomycin and vinblastine) regimens. Results On multivariate analysis with categorical forms, the 5-year freedom from progression survival was significantly lower in patients with stage IV or elevated value of platelets, eosinophils and ferritin at diagnosis. Furthermore, stage IV and eosinophils seem to maintain their predictive value independently of interim (after IV cycles of chemotherapy) positron emission tomography. Conclusion Using the combination of four simple markers such as stage IV and elevated levels of platelets, ferritin and eosinophils, it is possible to classify the patients into subgroups with very different outcomes.

The prognostic value of biological markers in paediatric Hodgkin lymphoma / Farruggia, P.; Puccio, G.; Sala, A.; Todesco, A.; Buffardi, S.; Garaventa, A.; Bottigliero, G.; Bianchi, M.; Zecca, M.; Locatelli, F.; Pession, A.; Pillon, M.; Favre, C.; D'Amico, S.; Provenzi, M.; Trizzino, A.; Zanazzo, G. A.; Sau, A.; Santoro, N.; Murgia, G.; Casini, T.; Mascarin, M.; Burnelli, R.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 52:(2016), pp. 33-40. [10.1016/j.ejca.2015.09.003]

The prognostic value of biological markers in paediatric Hodgkin lymphoma

Locatelli F.;
2016

Abstract

Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, procarbazine, doxorubicin, bleomycin and vinblastine) regimens. Results On multivariate analysis with categorical forms, the 5-year freedom from progression survival was significantly lower in patients with stage IV or elevated value of platelets, eosinophils and ferritin at diagnosis. Furthermore, stage IV and eosinophils seem to maintain their predictive value independently of interim (after IV cycles of chemotherapy) positron emission tomography. Conclusion Using the combination of four simple markers such as stage IV and elevated levels of platelets, ferritin and eosinophils, it is possible to classify the patients into subgroups with very different outcomes.
2016
hodgkin lymphoma; paediatric; prognostic factor
01 Pubblicazione su rivista::01a Articolo in rivista
The prognostic value of biological markers in paediatric Hodgkin lymphoma / Farruggia, P.; Puccio, G.; Sala, A.; Todesco, A.; Buffardi, S.; Garaventa, A.; Bottigliero, G.; Bianchi, M.; Zecca, M.; Locatelli, F.; Pession, A.; Pillon, M.; Favre, C.; D'Amico, S.; Provenzi, M.; Trizzino, A.; Zanazzo, G. A.; Sau, A.; Santoro, N.; Murgia, G.; Casini, T.; Mascarin, M.; Burnelli, R.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 52:(2016), pp. 33-40. [10.1016/j.ejca.2015.09.003]
File allegati a questo prodotto
File Dimensione Formato  
Farruggia_Prognostic-value_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 625.06 kB
Formato Adobe PDF
625.06 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1487551
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact